Henry Ford Health System Of Detroit To Enroll And Treat Patients In CEL-SCI (CVM)’s Phase 3 Head And Neck Cancer Clinical Trial
4/8/2014 10:03:18 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Henry Ford Health System in Detroit, Michigan is the latest U.S. clinical center to join the Company’s Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI is currently expanding and accelerating patient enrollment in its trial. The Company expects to rapidly expand the number of clinical sites active in the U.S. As the world’s largest Phase III trial for head and neck cancer, CEL-SCI’s study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries by the end of 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by